filmov
tv
Panel: Gene and Antisense Therapy for Neurodegeneration - John Ravits, UCSD
Показать описание
PANEL: GENE AND ANTISENSE THERAPY FOR NEURODEGENERATION
This session will provide an in-depth update on clinical and preclinical programs of AAV9 gene therapy for spinal muscular atrophy, antisense oligonucleotide therapy for ALS and growth factor gene therapy for Alzheimer’s disease.
Making Sense of Antisense: ASO Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia:
John Ravits, Ph.D., Professor of Clinical Neuroscience, UC San Diego
This session will provide an in-depth update on clinical and preclinical programs of AAV9 gene therapy for spinal muscular atrophy, antisense oligonucleotide therapy for ALS and growth factor gene therapy for Alzheimer’s disease.
Making Sense of Antisense: ASO Therapy Development for C9orf72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia:
John Ravits, Ph.D., Professor of Clinical Neuroscience, UC San Diego
0:24:54
Panel: Gene and Antisense Therapy for Neurodegeneration - John Ravits, UCSD
0:28:01
Panel: Gene and Antisense Therapy for Neurodegeneration - Mark Tuszynski, UCSD
0:01:00
Panel: Gene and Antisense Therapy for Neurodegeneration - Mark Tuszynski, UCSD
0:25:30
HOT TOPICS | Gene Expression | Modulating with Oligonucleotide-based Therapies
0:23:35
Antisense oligonucleotide therapy
0:03:51
Treating Disease at the RNA Level with Oligonucleotides
1:16:47
Gene and Antisense Oligonucleotide Therapy Approaches for GBE1-deficient Diseases
1:04:31
Antisense Oligonucleotide based Therapies for Inherited Retinal Diseases From Mutation to Clinical
0:57:48
Antisense Oligonucleotides for Prion Disease
0:56:31
Webinar: Targeting RNA Structure as a Therapeutic Strategy
0:49:43
Track 4: Making Sense of Antisense and Other Oligonucleotide Therapies
0:11:32
How Antisense Technology Works
0:49:10
2018 FSHD Connect Therapeutics Panel Part 2
0:58:05
Antisense Oligonucleotide Therapy for ALS
0:39:56
2022 WMIF | RNA Therapeutics | Lessons Learned
0:23:13
Don Cleveland: 2018 Breakthrough Prize Symposium
0:23:23
Oligonucleotides as a New Therapeutic Class: Progress Report & Prescription
0:24:59
Gene Expression 101 with Dr. David Segal
0:44:31
Developing an Antisense Oligonucleotide Therapy for APBD Patients with the Intronic Mutation
0:31:01
Addressing Delivery Hurdles in the Translation of Oligonucleotide Therapeutics
2:03:11
Education Workshop (2021 Annual Meeting)
1:03:42
David Corey: Guidelines for Experiments using Antisense Oligonucleotides and Double-Stranded RNAs
0:21:46
In the Pipeline: Gene Therapy - Audentes Therapeutics
0:59:20
Anastasia Khvorova: RNAi-based Therapeutics: 2018 Outlook
Комментарии